101 related articles for article (PubMed ID: 7826985)
1. Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Häkel C; Ueda Y; Tsuchya H; Herrera A; Blasius S; Roessner A
Zentralbl Pathol; 1994 Nov; 140(4-5):363-9. PubMed ID: 7826985
[TBL] [Abstract][Full Text] [Related]
2. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells.
Lollini PL; Landuzzi L; Frabetti F; Rossi I; Nicoletti G; Scotlandi K; Serra M; Baldini N; De Giovanni C; Nanni P
Clin Cancer Res; 1998 Aug; 4(8):1843-9. PubMed ID: 9717810
[TBL] [Abstract][Full Text] [Related]
3. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
[TBL] [Abstract][Full Text] [Related]
4. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Kushlinskii NE; Yusifov AI; Gershtein ES; Solov'ev YN; Trapeznikov NN
Bull Exp Biol Med; 2001 Aug; 132(2):780-2. PubMed ID: 11713566
[TBL] [Abstract][Full Text] [Related]
7. Sarcomas of bone in childhood: pathologic aspects.
Kissane JM; Askin FB; Nesbit ME; Vietti TJ; Burgert EO; Cangir A; Gehan EA; Perez CA; Pritchard DJ; Tefft M
Natl Cancer Inst Monogr; 1981 Apr; (56):29-41. PubMed ID: 6272116
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
9. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
10. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
[TBL] [Abstract][Full Text] [Related]
11. [Cytogenesis and histogenesis of malignant and semimalignant bone tumors].
Roessner A; Grundmann E
Veroff Pathol; 1984; 122():1-195. PubMed ID: 6091360
[TBL] [Abstract][Full Text] [Related]
12. Round cell tumours of bone.
Roessner A; Jürgens H
Pathol Res Pract; 1993 Dec; 189(10):111-36. PubMed ID: 8183732
[TBL] [Abstract][Full Text] [Related]
13. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression in pediatric sarcomas.
Dickens DS; Kozielski R; Khan J; Forus A; Cripe TP
Pediatr Dev Pathol; 2002; 5(4):356-64. PubMed ID: 12024286
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic studies on fine-needle aspiration samples from osteosarcoma and Ewing's sarcoma.
Akerman M; Dreinhöfer K; Rydholm A; Willén H; Mertens F; Mitelman F; Mandahl N
Diagn Cytopathol; 1996 Jul; 15(1):17-22. PubMed ID: 8807247
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
18. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Buø L; Bjørnland K; Karlsrud TS; Kvale D; Kjønniksen I; Fodstad O; Brandtzaeg P; Johansen HT; Aasen AO
Anticancer Res; 1994; 14(6B):2445-51. PubMed ID: 7872665
[TBL] [Abstract][Full Text] [Related]
19. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
